FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2576475417> ?p ?o ?g. }

• W2576475417 abstract "Abstract CD19 is a pan-B cell surface receptor expressed from early stages of pre-B cell development through terminal differentiation into plasma cells. It is an attractive target for cancers of lymphoid origin since it is expressed on the vast majority of Non-Hodgkin Lymphoma (NHL) as well as different types of leukemia, including those (e.g. pediatric ALL) lacking CD20 expresion. The majority of NHL patients will relapse after the current treatment regimen of chemotherapy combined with rituximab (CHOP-R) despite major improvements in response rates and progression free survival. Thus salvage regimens with novel non-cross resistant antibody therapies are warranted. Here we present the characterization of a novel Fc-engineered and humanized anti-CD19 antibody (XmAb™ CD19) that was generated using our XmAb™ antibody engineering technologies. This novel antibody is highly cytotoxic against a panel of lymphoma and leukemia cell lines as well as primary cancer cells. The main features of this antibody are: increased affinity for Fc gamma receptors (FcgR), improved effector function, and significantly increased antitumor potency. Humanization and affinity maturation technologies were applied to this antibody in order to: decrease immunogenicity, increase affinity, and increase stability of the engineered antibody. Since internalization is expected to impact a naked antibody’s effector functions, we assayed its internalization rate using Eu-labeled XmAbCD19 and observed an unexpectedly low rate of internalization. Therefore, we proceeded to investigate several direct and indirect (Fc-mediated) mechanisms of antibody-mediated cytotoxicity. The potency of XmAbCD19 in antibody-dependent cell-mediated cytotoxicity (ADCC) increased 10- to 100-fold relative to a native/non Fc-engineered version (CD19-IgG1) of the antibody in a screen of 16 NHL and leukemia cell lines (chronic lymphocytic leukemia [CLL], B-cell acute lymphoblastic leukemia [B-ALL], hairy cell leukemia [HCL], follicular lymphoma [FL], mantle cell lymphoma [MCL], chronic myelogenous leukemia [CML], and Burkitt’s lymphoma [BL]). ADCC potency (EC50) and efficacy (% Lysis) of the Fc-engineered anti-CD19 antibody were superior to that of rituximab: in CLL - 10- and 1.5-fold higher, in B-ALL - 10- and 100-fold higher, and in HCL - 6- and 1.2-fold higher, respectively; unlike XmAbCD19 native CD19-IgG1 mediated little ADCC. Moreover, XmAbCD19 mediated potent ADCC of primary patient-derived ALL cells that was also significantly increased in potency and efficacy relative to rituximab and CD19 IgG1. Furthermore, XmAbCD19 demonstrated 50-fold increased antibody-dependent cellular phagocytosis (ADCP) relative to CD19-IgG1. Finally, XmAbCD19 exhibited robust anti-proliferative activity that was 10-fold more potent than that of rituximab. In order to facilitate preclinical toxicology studies with XmAbCD19, we assayed its cross-reactivity with non-human primate (NHP) species CD19 (cynomolgus and rhesus monkeys). In contrast to the parental murine antibody, the affinity-optimized humanized XmAbCD19 reacted with B cells from both NHP species. In summary, our data suggest that our anti-CD19 Fc variant antibody engineered for increased effector function is a promising next-generation immunotherapeutic for a variety of leukemias and lymphomas." @default.
• W2576475417 created "2017-01-26" @default.
• W2576475417 creator A5001086229 @default.
• W2576475417 creator A5012207265 @default.
• W2576475417 creator A5016639606 @default.
• W2576475417 creator A5032523934 @default.
• W2576475417 creator A5056285194 @default.
• W2576475417 creator A5067216355 @default.
• W2576475417 creator A5071386810 @default.
• W2576475417 creator A5079929806 @default.
• W2576475417 creator A5081789226 @default.
• W2576475417 date "2007-11-16" @default.
• W2576475417 modified "2023-09-28" @default.
• W2576475417 title "XmAb™ Fc Engineered Anti-CD19 Monoclonal Antibody with Enhanced In Vitro Efficacy Against Lymphoma and Leukemia." @default.
• W2576475417 doi "https://doi.org/10.1182/blood.v110.11.2335.2335" @default.
• W2576475417 hasPublicationYear "2007" @default.
• W2576475417 type Work @default.
• W2576475417 sameAs 2576475417 @default.
• W2576475417 citedByCount "0" @default.
• W2576475417 crossrefType "journal-article" @default.
• W2576475417 hasAuthorship W2576475417A5001086229 @default.
• W2576475417 hasAuthorship W2576475417A5012207265 @default.
• W2576475417 hasAuthorship W2576475417A5016639606 @default.
• W2576475417 hasAuthorship W2576475417A5032523934 @default.
• W2576475417 hasAuthorship W2576475417A5056285194 @default.
• W2576475417 hasAuthorship W2576475417A5067216355 @default.
• W2576475417 hasAuthorship W2576475417A5071386810 @default.
• W2576475417 hasAuthorship W2576475417A5079929806 @default.
• W2576475417 hasAuthorship W2576475417A5081789226 @default.
• W2576475417 hasConcept C159654299 @default.
• W2576475417 hasConcept C203014093 @default.
• W2576475417 hasConcept C2778461978 @default.
• W2576475417 hasConcept C2780653079 @default.
• W2576475417 hasConcept C40677261 @default.
• W2576475417 hasConcept C502942594 @default.
• W2576475417 hasConcept C542903549 @default.
• W2576475417 hasConcept C86803240 @default.
• W2576475417 hasConceptScore W2576475417C159654299 @default.
• W2576475417 hasConceptScore W2576475417C203014093 @default.
• W2576475417 hasConceptScore W2576475417C2778461978 @default.
• W2576475417 hasConceptScore W2576475417C2780653079 @default.
• W2576475417 hasConceptScore W2576475417C40677261 @default.
• W2576475417 hasConceptScore W2576475417C502942594 @default.
• W2576475417 hasConceptScore W2576475417C542903549 @default.
• W2576475417 hasConceptScore W2576475417C86803240 @default.
• W2576475417 hasLocation W25764754171 @default.
• W2576475417 hasOpenAccess W2576475417 @default.
• W2576475417 hasPrimaryLocation W25764754171 @default.
• W2576475417 hasRelatedWork W1985837387 @default.
• W2576475417 hasRelatedWork W2041126185 @default.
• W2576475417 hasRelatedWork W2090404922 @default.
• W2576475417 hasRelatedWork W2115013237 @default.
• W2576475417 hasRelatedWork W2122584026 @default.
• W2576475417 hasRelatedWork W2146504299 @default.
• W2576475417 hasRelatedWork W2476973230 @default.
• W2576475417 hasRelatedWork W3180303887 @default.
• W2576475417 hasRelatedWork W3193741685 @default.
• W2576475417 hasRelatedWork W36926049 @default.
• W2576475417 isParatext "false" @default.
• W2576475417 isRetracted "false" @default.
• W2576475417 magId "2576475417" @default.
• W2576475417 workType "article" @default.